HLIT vs JKS

HLIT exhibits severe fundamental divergence, with a Piotroski F-Score of 4/9 indicating only stable-to-weak health and a Graham Number of $0.88 that suggests the current price of $10.56 is massively overvalued. The company is facing a critical operational crisis, evidenced by a YoY revenue collapse of -55.80% and a Q/Q revenue decline of -123.87%. While the balance sheet remains healthy with low debt (Debt/Equity 0.35) and strong liquidity (Current Ratio 2.50), these are lagging indicators that cannot offset the rapid deterioration in top-line growth and profitability. The extreme P/E ratio of 1056.00 further highlights a valuation disconnected from current earnings reality.

JKS exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic YoY EPS decline of 1548.3%. While the stock appears cheap on a Price-to-Book (0.51) and Price-to-Sales (0.02) basis, these are classic 'value trap' indicators given the negative profit margins and crashing revenue growth. The dividend is fundamentally unsustainable with a payout ratio of 388.48%, suggesting the company is returning capital it does not have. Despite bullish analyst targets, the deterministic health metrics signal a high risk of further deterioration.